comparative efficiency and safety GIBP.
Now there is a number of works comparing efficiency and safety GIBP in rheumatology, including, at treatment juvenilnyh idiopathic arthritises (table 1 [67]).
Table №1 Comparison of efficiency and safety GIBP according to the world researches.
| Group of authors | Design of research | Studied preparations | effektiv nost | bezopas nost |
| Janneke Anink, Marieke H. Otten, 2011 | The regular review 11 randomizirovanny researches | JUIA sust. - Etanertsept, abatatsept, adalimumab JUIA sist. - anakinra, totsilizumab and kanakinumab | 0,05 | |
| P Lahdenne, 2008 | nerandomizirovannoe prospektivnoe research | infliksimaba n=14 etanertsepta n=10 | 0,05 | |
| V., 2008 | Frequency of development and degree of expression of the undesirable phenomena was compared | infliksimab n=68, etanertsept n=95 | 0,05 | |
| Tepikina E.N., 2011 | Indirect comparison | Infliksimab, abatatsept | 0,05 | |
| Lamot. L., 2011 | Indirect comparison | Infliksimab, etanertsept | 0,05 | |
| JAgudina RIVER I, 2011 | The pharmacological analysis of data of the Netherlands register on application etanertsepta and double blind platsebo - controllable clinical research abatatsepta at JUIA. | Etanertsept - 148, abatatsept - 190 | Etaner tsept more effektiv nyj in comparison with abatatse ptom | Etaner tsept more bezopas nyj on it is compared iju with abatatse ptom |
| Gorjajnov S.V., 2011 | Indirect comparison 3 RKI | etanertsept, abatatsept and adalimumab | 0,05 |
Algorithms of appointment GIBP are developed at this or that form JUIA. So, in the table № 2 the algorithm of treatment JUIA is presented, to the American board by the rheumatologist from 2011 [84]. From the table follows, that at oligo - and polyarticulary system variant JUIA without extraarticular implications by preparations of the first line inhibitors FNO are.
Table №2. Algorithm of appointment GIBP ACR 2011.
Algorithm GIBT of therapy JURA
ACR 2011
| Oligoartikuljarnyj | The polyarticulary | System without system implications (c aktiv.artritom) | System with system implications |
| 1st line: i-fno 2 I линия:и-ФНО +ГК/НПВ | 1st линия:и-ФНО 2 I a line: i-fno + GK/NPV 3 I a line: 2ji-FnO or abatatsept | 1st линия:и-ФНО илианакинра* 2 I линия:и-ФНО илианакинра* + GK/NPVP 3 I a line: abatatsept | 1st line: anakinra 2 I a line: anakinra + NPVP |
* More effectively at early (
Скачать оригинал источника
Other medical related information comparative efficiency and safety GIBP.:
- THE TABLE OF CONTENTS
- INTRODUCTION
- Infliksimab
- Abatatsept
- comparative efficiency and safety GIBP.
- Chapter 3.1. Efficiency and safety infliksimaba at children with JUIA.
- CHAPTER 4.1. Efficiency and safety GIBP comparison (infliksimaba, etanertsepta and abatatsepta) at children with system variant JUIA.
- CHAPTER 4.2. Efficiency and safety GIBP comparison (infliksimaba, etanertsepta and abatatsepta) at children with articulate variant JUIA.
- CHAPTER №5 DISCUSSION